Preliminary list as of February 23

Academia Sinica
Genistein-Based BODIPY Probe and Its PROTAC Degrader to Suppress Colorectal Cancer via Signal Transducer and Activator of Transcription 1 (STAT1)

Cambridge Crystallographic Data Center
Gaining Insights from the Cambridge Structural Database (CSD)

Carterra, Inc.
Deep Characterization of Binding Kinetics for 210 Kinase Inhibitors Against 80+ Kinases

Cayman Chemical Company
Apolipoprotein E: Purification, Characterization, and Lipid Nanoparticle Uptake Enhancement

Chd4, Foxp3+ Treg Cells and Tumor Immunotherapy

MICRO-TAG: A Novel Fluorescence-Based Real-Time Cellular Target Engagement Platform for Drug Discovery

Pan-RAS Inhibitor ADT-007: A Novel Mechanism of Antitumor Selectivity in PDAC and CRC Carcinoma Models

Probing Monomer – Dimer and Conformational Transitions of PLK1 Using Catalytic and Polo-Box Domain Inhibitors

R9: A Novel NuRD Complex Inhibitor for Targeted Therapy in Triple Negative Breast Cancer (TNBC)

CellFree Sciences Co., Ltd.
CF-PPiD: A Cell-Free Human Protein Array Technology Using Proximity Biotinylation-Based Protein-Protein Interaction Identification

Charnwood Discovery
Integrated Drug Discovery –PD-1/PD-L1 Inhibitors

ChemPass Ltd.
A Knowledge-Based Fragment Library Design Platform and an In-Silico Platform for Rapid Fragment Optimization

Chemspace LLC
REAL Fragment Library: Efficient Fragment Growing Inside Enamine REAL Using Exit Vector Analysis

Chemspace LLC
Unveiling Hidden Treasures: Exploring Large Chemical Spaces with Machine Learning Models Trained on DNA-Encoded Libraries

CRX202, Selective AAK1 Inhibitor, Demonstrates Potent Efficacy in Animal Models of Neuropathic Pain

Concept Life Sciences
Introducing BioPALS – A Versatile Hit Identification Technology Powered by AI and Enabled by GCI

PROTAC Design Using Electrostatic Complementarity™

Experimental Strategies for Fragment-Based Screening of Challenging Targets Using Surface Plasmon Resonance

Domainex Ltd.
Accelerated Direct-to-Biology Facilitated by Plate-Based Reaction Optimisation and a Partial PROTAC Library

Ehime University
Development of Thalidomide Derivatives for Controlling Neosubstrate Degradation

Eli Lilly and Company
Analysis of HDAC6:Tubulin Interaction Using Affinity Selection Mass Spectrometry

F. Hoffmann-La Roche Ltd.
Mapping Trace Amine-Associated Receptor 1 with Positron Emission Tomography

Gyeongsang National University
Structural Analysis of the Complex Model of Ambrosia artemisiifolia PPO2 and OMN for Understanding Herbicide Resistance Mechanisms

HITS Co., Ltd.
Hyper Lab: Drug Discovery Platform Using a Deep Learning-Based Protein-Ligand Interaction Prediction Model

Katholieke Universiteit Leuven
Rational Fragment-Based Approach to Targeting the LEDGF PWWP Domain in HIV Infection and MLL-r Leukemia

Life Chemicals, Inc.
Covalent Inhibitor Screening Libraries

Life Chemicals, Inc.
Fragment Compound Libraries from Life Chemicals

Life Chemicals, Inc.
Screening Compound Libraries for HTS and Lead Discovery Projects

Malvern Panalytical
Kinetic Screening Using Grating Coupled Interferometry (GCI) – Highly Sensitive Biosensor-Based Assays Enable the Identification of Weak Fragment Hits Across a Diverse Set of Challenging Targets

Medical University of Graz
Modulation of Calcium-Release Activated Channels by Peptide-Based Macrocycles

Monash University
Fragment-Based Development of nM FABP4 Binders Through Rapid SPR Screening of Crude Reaction Libraries

Monash University
To Affinity and Beyond: Biophysical Methods Enable Fragment-to-Lead Development for Fatty Acid Binding Protein 4

National Health Research Institutes, Taiwan
Discovering Furanopyrimidine-Based Dual MER and AXL Inhibitors as Immunomodulatory Anticancer Treatments

National Institutes of Health, National Institute of Mental Health
Opportunities for the Development of Neurotherapeutics: NIH Blueprint Neurotherapeutics Network (BPN)

National Institutes of Health, National Institute of Neurological Disorders and Stroke
Opportunities for the Development of Neurotherapeutics: NINDS Division of Translational Research

Newcastle University
Covalent Fragment Optimization Applied to Epidermal Growth Factor Receptor Tyrosine Kinase

Newcastle University
Fragment Expansion with NUDELs - Poised DNA-Encoded Libraries

Protein Stable / Applied Photophysics, Inc.
Complete Thermal Melting Characterization of the NISTmAb with the SUPR-DSF Microplate Reader

Rgenta Therapeutics
Successful Application of an RNA Splicing Modulator Platform to Develop Molecules Targeting the Transcription Factor MYB to Treat Solid and Blood Cancers

Sanford Burnham Prebys Medical Discovery Institute
Discovery and Characterization of Novel Fragment Binders of the VHR Phosphatase as a Drug Target for Cervix Cancer

Sanford Burnham Prebys Medical Discovery Institute
Discovery and Development of Novel Autophagy Inhibiting ATG13 Degrading Compounds

Simulations Plus, Inc.
Best of Both Worlds: An Expansion of the State of the Art pKa Model with Data from Three Industrial Partners

Sygnature Discovery
Building Diverse Hit-Finding Collections Through Novel Chemistries - Sygnature Discovery’s Unique PRISM Library for HTS

Sygnature Discovery
The Sygnature CHARMED Platform: Combinatorial High-Throughput Assembly and Review of Molecular Degraders

University of Hong Kong
Develop New Chemical Tool and Chemo-Proteomic Experiments for Studying Superoxide (O2•-) Biology

University of Kansas
cgSHAPE-seq Informs the Binding Site of RNA-Degrading Chimeras Targeting SARS-CoV-2 5’ UTR

University of Kansas
Development of PMO-Based RNA Degraders for the Treatment of Parkinson's Disease

University of Michigan
Fragment-Based Discovery of Potent PRC1 Inhibitor with In Vivo Efficacy in Leukemia

University of Southern Denmark
Utilizing Rapid Active Learning Docking as an Efficient Tool to Explore Multiple Novel Binding Sites in Parallel

Vipergen Aps
DELs in Cells: Turn-Around-Time Optimized

Viva Biotech Ltd.
Unleash the Greatest Potential of DEL: Viva’s High-Value, High-Capability DNA-Encoded Library Platform

Yale University
CardioGenAI: A Machine Learning-Based Framework for Re-Engineering Drugs for Reduced Cardiotoxicity